4 results
The aim of the study is to compare magnesiumhydroxide and polyethylene glycol/electrolytes with regard to the prevention of constipation and side-effects in palliative care cancer patients starting with opioids.
Part A - CX-2009 Monotherapy: Every 21-Day Dosing RegimenThe primary objective of Part A is to determine the safety profile of CX-2009, the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D), and the dose-limiting toxicities(DLTs) of CX-…
Primary Objective: In patients with advanced cancer, starting with opioids for pain: • To prove non-inferiority of magnesium hydroxide to macrogol/electrolytes in the prevention of OIC, based on the percentage of patients without obstipation (BFI-…
To show the protective value and to measure cost effectiveness of higher Ig dosing on progression of lung disease in PAD.